Background Multimorbidity and the associated use of multiple medicines (polypharmacy), is
common in the older population. Despite this, there is no consensus definition for …

Background Polypharmacy (PP) and potentially inappropriate medications (PIM) are highly
prevalent in older adults with cancer. This study systematically reviews the associations of …

Objectives To investigate the relationship between polypharmacy and frailty. Design
Longitudinal, observational cohort study. Setting Saarland, Germany. Participants 3,058 …

Purpose Polypharmacy is prevalent in older adults starting cancer treatment and associated
with potentially inappropriate medications (PIM), potential drug-drug interactions (DDI), and …

Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess
and improve due to variations in definitions of the problem and the heterogeneous methods …

Purpose: Restrictive clinical trial eligibility criteria (EC) limit the number of patients who can
enroll and potentially benefit from protocol-driven, investigational treatment plans and …

Polypharmacy is a well known problem in elderly patients in general, but its prevalence and
effects in patients with cancer are less clear, particularly in end-of-life settings. This Review …

Abstract Purpose To investigate:(1) the cross-sectional association between polypharmacy,
hyperpolypharmacy and presence of prefrailty or frailty;(2) the risk of incident prefrailty or …

Purpose Polypharmacy is often defined as use of 'five-or-more-medications'. However, the
optimal polypharmacy cut-point for predicting clinically important adverse events in older …

Objective To estimate the prevalence of polypharmacy among Australians aged 70 years or
more, 2006–2017. Design, setting and participants Analysis of a random 10% sample of …